Artwork

Content provided by Washington University School of Medicine in St. Louis and Jim Dryden. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Washington University School of Medicine in St. Louis and Jim Dryden or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Smoking-genetics study

2:58
 
Share
 

Archived series ("Inactive feed" status)

When? This feed was archived on January 20, 2022 04:34 (2+ y ago). Last successful fetch was on April 07, 2020 16:45 (4+ y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage episode 164816692 series 1299386
Content provided by Washington University School of Medicine in St. Louis and Jim Dryden. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Washington University School of Medicine in St. Louis and Jim Dryden or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

A study at Washington University School of Medicine in St. Louis may aid efforts to tailor smoking-cessation treatments to cigarette smokers, based on their DNA. The researchers are recruiting 720 smokers from the St. Louis area who want to kick the habit. Study participants will provide DNA samples, from saliva, that will be analyzed to identify genetic variations that influence smoking behavior, lung cancer risk and the effectiveness of smoking-cessation treatments.

SMOKING IS LINKED TO CANCER AND TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE. RESEARCH HAS SHOWN THAT IT SHORTENS A PERSON�S LIFESPAN BY ABOUT 12 YEARS. BUT STILL, MANY PEOPLE SMOKE, AND IT�S VERY DIFFICULT TO QUIT. SO RESEARCHERS AT WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS ARE AIMING TO MATCH UP TREATMENTS WITH THE DNA OF INDIVIDUAL SMOKERS. THEY�RE RECRUITING SMOKERS WHO WANT TO QUIT, AND THEY HOPE TO LEARN WHETHER IT�S POSSIBLE TO MATCH SMOKERS WITH THERAPIES, BASED ON GENETIC INFORMATION. JIM DRYDEN REPORTS�

MOST SMOKERS KNOW THE HABIT IS BAD FOR THEM AND WANT TO QUIT, BUT THAT DOESN�T MEAN THEY CAN. WASHINGTON UNIVERSITY NICOTINE RESEARCHER LI-SHIUN CHEN SAYS MOST PEOPLE WHO TRY TO QUIT FAIL, AND SO HER RESEARCH GROUP HAS BEEN STUDYING DNA TO FIND WAYS TO IMPROVE THE ODDS FOR THOSE WHO WANT TO STOP SMOKING.
(act) :21 o/c evidence-based treatments

Quitting smoking is very hard. Most people who smoke have tried to
quit smoking multiple times throughout their life, and only about
5 percent succeed without the help of treatments. And even with
treatments, research shows that a person�s genes effect how they
respond to medications. So our goal is to help people quit smoking
with evidence-based treatments.

CHEN SAYS PREVIOUS RESEARCH HAS SHOWN THAT SMOKERS WITH HIGH-RISK GENE VARIANTS ARE LIKELY TO SMOKE LONGER AND DEVELOP CANCER SOONER THAN THOSE WHO SMOKE BUT DON�T HAVE THOSE DNA VARIATIONS.
(act) :16 o/c low-risk genotypes

People with the high-risk genetic markers, they are less likely
to quit on their own. They would have a delayed quitting by four
years, and they will have lung cancer, actually, four years earlier,
compared to those with the low-risk genotypes.

THE GOOD NEWS, SHE SAYS, IS PEOPLE WITH THE HIGH-RISK GENETIC MARKERS ALSO SEEM MORE LIKELY TO BENEFIT FROM NICOTINE-REPLACEMENT THERAPY.
(act) :17 o/c only counseling

The same group of people, with the high-risk genetic markers, is
more likely to respond to medication, and medications don�t help
everyone equally. It is possible that different smokers would need
different medications, or even some smokers require only counseling.

SO THE WASHINGTON UNIVERSITY RESEARCHERS ARE DIVIDING UP SMOKERS TRYING TO QUIT INTO 3 GROUPS: ONE GROUP WILL GET COUNSELING AND NICOTINE REPLACEMENT PATCHES AND LOZENGES; A SECOND WILL RECEIVE THE DRUG VARENICLINE, ALSO CALLED CHANTIX, PLUS COUNSELING; AND THE REST WILL GET 7 WEEKS OF COUNSELING BUT WON�T GET ANY DRUGS. CHEN SAYS BY COMPARING OUTCOMES AND LOOKING AT DNA, THIS STUDY COULD MAKE IT POSSIBLE TO TAILOR THERAPIES TO SMOKERS.
(act) :11 o/c genetic markers

Our goal is to match people up with the medication that is most
likely to help them and least likely to give them any side effects,
so we are going to look at multiple genetic markers.

STUDY PARTICIPANTS WILL PROVIDE A SALIVA SAMPLE PRIOR TO THE START OF THE STUDY. THEN CHEN AND HER COLLEAGUES WILL LOOK AT HOW SUCCESSFUL STUDY SUBJECTS ARE AT QUITTING AND LOOK FURTHER AT HOW THEIR GENETIC MARKERS WORK TOGETHER WITH THE TREATMENTS. SHE SAYS HER GROUP IS RECRUITING MORE THAN 700 PEOPLE AGES 21 AND OLDER, AND SHE SAYS THAT ALTHOUGH SOME OLDER SMOKERS THINK IT MAY BE TOO LATE FOR THEM TO HELP THEMSELVES BY QUITTING, CHEN SAYS IT�S NEVER TOO LATE, AND EVEN OLDER SMOKERS CAN ADD BACK YEARS TO THEIR LIVES IF THEY KICK THE HABIT NOW.
(act) :13 o/c quit smoking

It can delay, or eliminate lung cancer. Research has shown that
it can also delay COPD, the chronic obstructive pulmonary disease
(or emphysema). It�s never too late to quit smoking.

CHEN SAYS EVERY SMOKER CAN BENEFIT SOMEHOW FROM QUITTING, AND SHE WANTS TO MAKE IT EASIER FOR THEM TO DO THAT. I�M JIM DRYDEN�

RUNS 2:59

  continue reading

50 episodes

Artwork
iconShare
 

Archived series ("Inactive feed" status)

When? This feed was archived on January 20, 2022 04:34 (2+ y ago). Last successful fetch was on April 07, 2020 16:45 (4+ y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage episode 164816692 series 1299386
Content provided by Washington University School of Medicine in St. Louis and Jim Dryden. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Washington University School of Medicine in St. Louis and Jim Dryden or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

A study at Washington University School of Medicine in St. Louis may aid efforts to tailor smoking-cessation treatments to cigarette smokers, based on their DNA. The researchers are recruiting 720 smokers from the St. Louis area who want to kick the habit. Study participants will provide DNA samples, from saliva, that will be analyzed to identify genetic variations that influence smoking behavior, lung cancer risk and the effectiveness of smoking-cessation treatments.

SMOKING IS LINKED TO CANCER AND TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE. RESEARCH HAS SHOWN THAT IT SHORTENS A PERSON�S LIFESPAN BY ABOUT 12 YEARS. BUT STILL, MANY PEOPLE SMOKE, AND IT�S VERY DIFFICULT TO QUIT. SO RESEARCHERS AT WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS ARE AIMING TO MATCH UP TREATMENTS WITH THE DNA OF INDIVIDUAL SMOKERS. THEY�RE RECRUITING SMOKERS WHO WANT TO QUIT, AND THEY HOPE TO LEARN WHETHER IT�S POSSIBLE TO MATCH SMOKERS WITH THERAPIES, BASED ON GENETIC INFORMATION. JIM DRYDEN REPORTS�

MOST SMOKERS KNOW THE HABIT IS BAD FOR THEM AND WANT TO QUIT, BUT THAT DOESN�T MEAN THEY CAN. WASHINGTON UNIVERSITY NICOTINE RESEARCHER LI-SHIUN CHEN SAYS MOST PEOPLE WHO TRY TO QUIT FAIL, AND SO HER RESEARCH GROUP HAS BEEN STUDYING DNA TO FIND WAYS TO IMPROVE THE ODDS FOR THOSE WHO WANT TO STOP SMOKING.
(act) :21 o/c evidence-based treatments

Quitting smoking is very hard. Most people who smoke have tried to
quit smoking multiple times throughout their life, and only about
5 percent succeed without the help of treatments. And even with
treatments, research shows that a person�s genes effect how they
respond to medications. So our goal is to help people quit smoking
with evidence-based treatments.

CHEN SAYS PREVIOUS RESEARCH HAS SHOWN THAT SMOKERS WITH HIGH-RISK GENE VARIANTS ARE LIKELY TO SMOKE LONGER AND DEVELOP CANCER SOONER THAN THOSE WHO SMOKE BUT DON�T HAVE THOSE DNA VARIATIONS.
(act) :16 o/c low-risk genotypes

People with the high-risk genetic markers, they are less likely
to quit on their own. They would have a delayed quitting by four
years, and they will have lung cancer, actually, four years earlier,
compared to those with the low-risk genotypes.

THE GOOD NEWS, SHE SAYS, IS PEOPLE WITH THE HIGH-RISK GENETIC MARKERS ALSO SEEM MORE LIKELY TO BENEFIT FROM NICOTINE-REPLACEMENT THERAPY.
(act) :17 o/c only counseling

The same group of people, with the high-risk genetic markers, is
more likely to respond to medication, and medications don�t help
everyone equally. It is possible that different smokers would need
different medications, or even some smokers require only counseling.

SO THE WASHINGTON UNIVERSITY RESEARCHERS ARE DIVIDING UP SMOKERS TRYING TO QUIT INTO 3 GROUPS: ONE GROUP WILL GET COUNSELING AND NICOTINE REPLACEMENT PATCHES AND LOZENGES; A SECOND WILL RECEIVE THE DRUG VARENICLINE, ALSO CALLED CHANTIX, PLUS COUNSELING; AND THE REST WILL GET 7 WEEKS OF COUNSELING BUT WON�T GET ANY DRUGS. CHEN SAYS BY COMPARING OUTCOMES AND LOOKING AT DNA, THIS STUDY COULD MAKE IT POSSIBLE TO TAILOR THERAPIES TO SMOKERS.
(act) :11 o/c genetic markers

Our goal is to match people up with the medication that is most
likely to help them and least likely to give them any side effects,
so we are going to look at multiple genetic markers.

STUDY PARTICIPANTS WILL PROVIDE A SALIVA SAMPLE PRIOR TO THE START OF THE STUDY. THEN CHEN AND HER COLLEAGUES WILL LOOK AT HOW SUCCESSFUL STUDY SUBJECTS ARE AT QUITTING AND LOOK FURTHER AT HOW THEIR GENETIC MARKERS WORK TOGETHER WITH THE TREATMENTS. SHE SAYS HER GROUP IS RECRUITING MORE THAN 700 PEOPLE AGES 21 AND OLDER, AND SHE SAYS THAT ALTHOUGH SOME OLDER SMOKERS THINK IT MAY BE TOO LATE FOR THEM TO HELP THEMSELVES BY QUITTING, CHEN SAYS IT�S NEVER TOO LATE, AND EVEN OLDER SMOKERS CAN ADD BACK YEARS TO THEIR LIVES IF THEY KICK THE HABIT NOW.
(act) :13 o/c quit smoking

It can delay, or eliminate lung cancer. Research has shown that
it can also delay COPD, the chronic obstructive pulmonary disease
(or emphysema). It�s never too late to quit smoking.

CHEN SAYS EVERY SMOKER CAN BENEFIT SOMEHOW FROM QUITTING, AND SHE WANTS TO MAKE IT EASIER FOR THEM TO DO THAT. I�M JIM DRYDEN�

RUNS 2:59

  continue reading

50 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide